IP Library › Granted Patent US 6,953,858
Granted Patent B2
US 6,953,858 · App. 10/166,957 · Granted Oct 11, 2005

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Assignee: Agouron Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,953,858
App. No.
10/166,957
Granted
Oct 11, 2005
Kind
B2
Abstract

Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

Claims (37)

1. A compound having the formula

which includes all the possible stereoisomers,

wherein:

R 1 is phenyl, where said phenyl is substituted with one or more substituents independently selected from alkyl, halogen or hydroxyl;

R 2 is a C 2 -C 6 alkenyl group or a C 2 -C 6 alkynyl group, wherein said alkenyl or alkynyl group is a straight or branched chained group, and

where said alkenyl or alkynyl group is unsubstituted or is substituted by one or more halogen substituents;

R 2′ is H;

X is

wherein R x is H;

Z is S, SO or SO 2 ;

R 3 , R 4 , R 5 , R 8 and R 8′ are each H; and

R 6 and R 7 are each methyl;

or a prodrug, pharmaceutically acceptable salt or solvate thereof.

2. The compound, prodrug, pharmaceutically acceptable salt, or pharmaceutically acceptable solvate according to claim 1 , having the formula:

3. The compound, prodrug, pharmaceutically acceptable salt, or pharmaceutically acceptable solvate according to claim 1 , having the formula:

4. The compound, prodrug, pharmaceutically acceptable salt, or pharmaceutically acceptable solvate according to claim 1 , having the formula:

5. The compound according to claim 1 , wherein R 2 is a C 2 -C 6 alkenyl group.

6. The compound according to claim 1 , wherein R 2 is a C 2 -C 6 alkynyl group.

7. A compound selected from:

or a prodrug, pharmaceutically acceptable salt or solvate thereof.

8. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

9. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

10. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

11. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

12. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

13. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

14. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

15. A compound of formula:

or pharmaceutically acceptable salt or solvate thereof.

16. The compound of claim 4 , wherein Z is S.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2003
From: KOCH, STACIE S. CANAN; ALEXANDER, THERESE N.; JEWELL, TAYNA; KUCERA, DAVID J.; REICH, SIEGFRIED H.; SKALITZKY, DONALD J.; VIRGIL, SCOTT C.; BURKE, BENJAMIN J.; MITCHELL, LENNERT J.; LINTON, MARIA A.; TATLOCK, JOHN H.; VARNEY, MICHAEL D.; WEBBER, STEPHEN E.; WORLAND, STEPHEN T.; BARVIAN, MARK; BOLTON, GARY; BOYER, FREDERICK E.; HOLLER, TOD; JOSYULA, VARA PRASAD; MACHAK, JEFF; MURPHY, SEAN T.; MELNICK, MICHAEL
To: AGOURON PHARMACEUTICALS, INC.
Reel/Frame 014067/0390 →
Continuity (3)
Provisional Application 6029746000 · Jun 11, 2001
Provisional Application 6029772900 · Jun 11, 2001
Related Publication 20030153507A1 · Aug 14, 2003